Versant Venture Capital Vi, L.P. has bought stock on 4 days since Nov 2019
10% owner at Monte Rosa Therapeutics, Inc., and 7 other companies
SEC CIK 0001687880 · Filings on SEC.gov ↗
Versant Venture Capital Vi, L.P.'s record
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Companies
- GLUE Monte Rosa Therapeutics, Inc.10% owner
- BDTX Black Diamond Therapeutics, Inc.10% owner
- TPST Tempest Therapeutics, Inc.10% owner
- IPSC Century Therapeutics, Inc.10% owner
- OYST Oyster Point Pharma, Inc.10% owner
- GRPH Graphite Bio, Inc.10% owner
- AKRO Akero Therapeutics, Inc.10% owner
- PASG Passage Bio, Inc.10% owner
Every filing
32 filings since Nov 2019, newest first
Monte Rosa Therapeutics, Inc.
10% owner
Monte Rosa Therapeutics, Inc.
10% owner
Monte Rosa Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Tempest Therapeutics, Inc.
10% owner
Century Therapeutics, Inc.
10% owner
Oyster Point Pharma, Inc.
10% owner
Graphite Bio, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Passage Bio, Inc.
10% owner
Black Diamond Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Akero Therapeutics, Inc.
10% owner
Oyster Point Pharma, Inc.
10% owner
About Versant Venture Capital Vi, L.P.
Versant Venture Capital VI, L.P. is a healthcare-focused venture capital fund affiliated with Versant Ventures, an American life sciences investment firm headquartered in San Francisco, California.( Versant Venture Capital VI, L.P. (often referred to as Versant Fund VI) was launched as Versant’s sixth healthcare fund with committed capital of approximately $400 million, targeting investments in biotechnology and related healthcare sectors in North America and Europe.( The fund operates as a limited partnership and is managed by Versant Ventures’ general partner entities, including Versant Ventures VI GP, L.P. and Versant Ventures VI GP-GP, LLC, which oversee investment strategy and portfolio governance.(
Versant Venture Capital VI, L.P. functions as an institutional investor and corporate insider in several public biotechnology companies, including Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), where it has reported beneficial ownership of 10% or more of the company’s shares in U.S. Securities and Exchange Commission filings.( Like other Versant funds, Fund VI is part of a broader platform that manages multiple healthcare funds with several billion dollars under management, backing companies discovering and developing novel therapeutics and other life sciences innovations.( Leadership and investment decisions for Versant Venture Capital VI, L.P. are carried out by the senior partners and investment professionals of Versant Ventures, a partnership founded in 1999 that has supported dozens of portfolio companies through IPOs and acquisitions.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.